Managing opioid withdrawal precipitated by buprenorphine with buprenorphine.


Journal

Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440

Informations de publication

Date de publication:
05 2021
Historique:
revised: 21 09 2020
received: 04 02 2020
accepted: 10 11 2020
pubmed: 23 1 2021
medline: 27 11 2021
entrez: 22 1 2021
Statut: ppublish

Résumé

Buprenorphine is a partial opioid agonist commonly used to treat opioid dependence. The pharmacology of buprenorphine increases the risk of a precipitated opioid withdrawal when commencing patients on buprenorphine treatment, particularly when transferring from long acting opioids (e.g. methadone). There is little documented experience regarding the management of precipitated withdrawal. In our case, a patient developed a significant precipitated opioid withdrawal following buprenorphine administration, and was able to be successfully treated in hospital with further buprenorphine. This demonstrates that rapid increases in buprenorphine dose can be used as an effective treatment for buprenorphine-induced precipitated opioid withdrawal. The use of buprenorphine to manage withdrawal then allows the individual to continue on this highly effective treatment.

Identifiants

pubmed: 33480051
doi: 10.1111/dar.13228
pmc: PMC8248003
doi:

Substances chimiques

Analgesics, Opioid 0
Narcotic Antagonists 0
Buprenorphine 40D3SCR4GZ
Methadone UC6VBE7V1Z

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

567-571

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.

Références

Am J Addict. 2012 Sep-Oct;21(5):492-3
pubmed: 22882402
J Psychoactive Drugs. 2003 Apr-Jun;35(2):253-9
pubmed: 12924748
Drug Alcohol Depend. 2007 Oct 8;90(2-3):261-9
pubmed: 17517480
J Addict Med. 2018 May/Jun;12(3):234-240
pubmed: 29509558
Curr Drug Abuse Rev. 2012 Mar;5(1):52-63
pubmed: 22280332
J Subst Abuse Treat. 2010 Jul;39(1):51-7
pubmed: 20682186

Auteurs

Bridget Oakley (B)

Drug and Alcohol Services, South East Sydney Local Health District, Sydney, Australia.

Hester Wilson (H)

Drug and Alcohol Services, South East Sydney Local Health District, Sydney, Australia.
School of Public Health and Community Medicine, UNSW Sydney, Sydney, Australia.

Victoria Hayes (V)

Drug and Alcohol Services, South East Sydney Local Health District, Sydney, Australia.
School of Public Health and Community Medicine, UNSW Sydney, Sydney, Australia.

Nicholas Lintzeris (N)

Drug and Alcohol Services, South East Sydney Local Health District, Sydney, Australia.
Division Addiction Medicine, University of Sydney, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH